Abstract | BACKGROUND: METHOD: Fifteen HIV-seropositive patients with DSM-IV major depressive disorder and a 21-item Hamilton Rating Scale for Depression (HAM-D) score of > or =18 were treated with open-label nefazodone for 12 weeks. Hamilton Rating Scale for Anxiety, HAM-D, Clinical Global Impressions scale, and Systematic Assessment for Treatment Emergent Events general inquiry (for safety and tolerability) scores were obtained at weeks 2, 4, 6, 8, and 12. RESULTS: Of 15 patients receiving nefazodone, 4 discontinued treatment (1 for adverse effects). Of 11 patients who completed the trial, 8 (73%) were classified as full responders with a 50% reduction in HAM-D scores and final CGI score of 1 or 2, and 10 (91%) were classified as partial responders (only 50% reduction in HAM-D scores). Nefazodone-treated subjects experienced few total adverse effects (mean = 1.5), no sexual side effects, and low rates of adverse-effect-related dropout (1 subject, 7%). CONCLUSION: Depressed HIV-seropositive outpatients respond to nefazodone comparably to other outpatient populations and have few adverse effects, suggesting that nefazodone may have a role in the treatment of depression in HIV-seropositive patients. Potential drug interactions with protease inhibitors indicate that it is essential to evaluate for appropriate dosing to avoid adverse effects and increase overall antidepressant efficacy.
|
Authors | A J Elliott, J Russo, K Bergam, K Claypoole, K K Uldall, P P Roy-Byrne |
Journal | The Journal of clinical psychiatry
(J Clin Psychiatry)
Vol. 60
Issue 4
Pg. 226-31
(Apr 1999)
ISSN: 0160-6689 [Print] United States |
PMID | 10221282
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Antidepressive Agents, Second-Generation
- Antidepressive Agents, Tricyclic
- Piperazines
- Protease Inhibitors
- Serotonin Uptake Inhibitors
- Triazoles
- nefazodone
|
Topics |
- Adult
- Ambulatory Care
- Antidepressive Agents, Second-Generation
(adverse effects, therapeutic use)
- Antidepressive Agents, Tricyclic
(adverse effects, therapeutic use)
- Comorbidity
- Depressive Disorder
(diagnosis, drug therapy, epidemiology)
- Drug Administration Schedule
- Drug Interactions
- Female
- HIV Seropositivity
(drug therapy, epidemiology)
- Humans
- Male
- Patient Dropouts
- Piperazines
- Protease Inhibitors
(adverse effects, pharmacology, therapeutic use)
- Psychiatric Status Rating Scales
(statistics & numerical data)
- Selective Serotonin Reuptake Inhibitors
(adverse effects, therapeutic use)
- Treatment Outcome
- Triazoles
(adverse effects, therapeutic use)
|